Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. - Wikidata - awgldk - TriplyDB

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

http://www.wikidata.org/entity/Q46847543

about

Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cells Mechanisms of bone metastases of breast cancer Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer Adjuvant systemic therapy in older women with breast cancer Trial watch - inhibiting PARP enzymes for anticancer therapy Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer Health Services Research and Health Economy - Quality Care Training in Gynaecology, with Focus On Gynaecological Oncology The sequential use of endocrine treatment for advanced breast cancer: where are we?Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer Pain related to cancer treatments and diagnostic procedures: a no man's land?Exemestane for breast cancer prevention: a critical shift?Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.Adjuvant therapy use among Appalachian breast cancer survivors German Recommendations for Diagnosis and Treatment of Breast Cancer 2008. What is New from the Breast Commission of the German Gynaecological Oncology Working Group (AGO)?Cancer treatment-related bone disease.Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries.Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis.Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status.Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.Late effects of cancer treatment in breast cancer survivors.American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.Status of adjuvant endocrine therapy for breast cancer.Adherence to hormone therapy among women with breast cancer Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000.Managing aromatase inhibitors in breast cancer survivors: not just for oncologists Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials.

P2860

Q24319134-503F0D6E-81E6-4551-B546-B71D97977E7C Q24597798-166222BF-E889-49E5-9A44-3A3091135DB5 Q24657145-423FA989-A81C-4C2D-8A17-EF94CE2EB25A Q24658633-4CB351BF-CB2D-4EA7-97D6-758551ABB951 Q26741523-D9185D1A-8360-4F2F-B8D8-15D231248EBF Q26745673-D08A3CD3-9A81-4385-8B38-7356E4248F76 Q26746212-3EA636C5-C60A-48E5-84B9-D85392EBBA0A Q26782449-DF1E6E62-E96E-435E-B5DC-1B951794D991 Q26782584-C18AC3FE-644A-4D7C-9528-D1A682EEC1F3 Q26862550-B8FC86B4-E8A5-4A56-85AA-3CC7BD3E8991 Q26996601-F4BE0C9F-01AB-46F2-9592-67B4A007A627 Q26997396-BB0A1157-5913-4C05-816A-6C45146B7F1C Q27002430-53A7B6C3-9047-4737-8FC4-F059273817D9 Q27008869-DF6FD827-0368-4AE8-B91C-09FA0FE43FE4 Q27026749-0FC8B509-3303-4FF3-AF4B-C9162A7188A6 Q27028211-8524CA5E-A841-4770-B611-473FD801BCA2 Q27851630-FE9A3C64-26A7-47C4-BA23-1D0DD47B239C Q27852637-955B26B8-1ABA-44CC-A78E-F614D03D56D5 Q30275906-AEB636B9-B5B9-4649-9A80-3CF36661CCAC Q30279083-99EC7B0B-73EF-48BB-A5A1-D3098E90C0AD Q30319696-511819DF-4C31-4BB0-9C45-8E3146B66907 Q30438185-9A61DBE9-2052-4F1B-BC4D-2D40846427B7 Q31120324-604B2E80-DFEE-46B4-9EAE-6F32A0A876F0 Q33494720-0191FBEB-5FF8-412B-AD06-A8A48E78C3CF Q33570282-1807464F-331B-4AD1-8D0B-EB2A6E243E40 Q33572119-F795A81B-5CD8-4D60-974C-9B9285334E5A Q33584258-42E2C3AA-2176-4F45-AFE2-260DB767016B Q33584483-89815331-6C3E-4275-B870-7771C6F0A615 Q33631047-ED18DD88-66BE-4F94-AD85-49CFECEDFB72 Q33658276-9C8FE316-D580-42E5-982A-335A6A03204E Q33676764-04C5E20E-3C55-44FB-8553-8CB26F966799 Q33739138-C5B861C6-E5EE-4605-B772-E2D9EF0F6FE5 Q33755452-D46C9F03-68DE-4F72-99A6-E062F7E4D07D Q33756969-F0F30E70-CFD3-4DA5-9ACE-DCF64ACDBCB8 Q33781027-28F3A94F-BCE2-4746-A77B-C2E9A03C9B72 Q33787731-109424FF-5231-446A-B03C-6A705DA089FA Q33793932-A24A5598-A4B6-4F98-884E-099B4972D099 Q33858930-B8282809-D20C-483D-9C8C-F9771B26CDDF Q33884184-368A91F3-19BC-4E35-97AF-FC7F36BCDB35 Q33939795-DF767448-499A-4C60-A7CF-E15A17A4E985

P2860

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

http://www.wikidata.org/entity/Q46847543

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Effect of anastrozole and tamo ...... th analysis of the ATAC trial.

@en

Effect of anastrozole and tamo ...... th analysis of the ATAC trial.

@nl

type

label

Effect of anastrozole and tamo ...... th analysis of the ATAC trial.

@en

Effect of anastrozole and tamo ...... th analysis of the ATAC trial.

@nl

prefLabel

Effect of anastrozole and tamo ...... th analysis of the ATAC trial.

@en

Effect of anastrozole and tamo ...... th analysis of the ATAC trial.

@nl

P1433

Q46847543-DAD1AAFF-1D67-4FCF-8513-A51D96F9F7EA

P1476

Q46847543-E2A581CC-F26C-40C6-AF8A-4C373FDAC6B3

P2093

Q46847543-5BF1DF5B-54A4-46EB-B3FE-0D95B459E90E

Q46847543-621EF35A-A8AE-4B12-8383-C6919CC592A4

Q46847543-8288E169-31FA-438B-BF96-1A683EA82415

Q46847543-8ACE77B0-5B09-46B6-9527-25395166EDCB

Q46847543-9C2700C5-C9A4-482C-A68A-1B565B5B6BAF

Q46847543-9ECB435E-E4A0-4345-83FA-41D5D501BEB6

Q46847543-CBBF9D71-D38A-43D6-8B74-E8B000CFB6AC

P304

Q46847543-A710F3D7-3726-4F14-A2E8-4791B756B732

P31

Q46847543-4AEA691E-A027-4B8D-9FC4-A8B2A8827C85

P356

Q46847543-7312C569-07CB-437F-9607-C77C353E884E

P433

Q46847543-A7B1D9A1-71C6-4969-A8FD-B524D7079F58

P478

Q46847543-7FC62859-524E-41CA-91E0-9737AC84DE74

P577

Q46847543-55DC73C7-6949-4E2E-BBC6-2A950D1D2D06

P698

Q46847543-0415F77B-D2B6-42FA-8474-12E39706D338

P356

S1470-2045(07)70385-6

P1433

The Lancet Oncology

P1476

Effect of anastrozole and tamo ...... th analysis of the ATAC trial.

@en

P2093

Aman Buzdar

http://www.w3.org/2001/XMLSchema#string

Anthony Howell

http://www.w3.org/2001/XMLSchema#string

Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group

http://www.w3.org/2001/XMLSchema#string

Jack Cuzick

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Tobias

http://www.w3.org/2001/XMLSchema#string

John F Forbes

http://www.w3.org/2001/XMLSchema#string

Michael Baum

http://www.w3.org/2001/XMLSchema#string

P304

45-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(07)70385-6

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18083636

http://www.w3.org/2001/XMLSchema#string